Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway

Neuroendocrinology

Volumn 96, Issue 3, 2012, Pages 228-237

  Bago Horvath, Zsuzsanna ^a   Sieghart, Wolfgang ^a   Grusch, Michael ^b   Lackner, Andreas ^b   Hayden, Hubert ^a   Pirker, Christine ^b   Komina, Oxana ^b   Wȩsierska Ga̧dek, Józefa ^b   Haitel, Andrea ^a   Filipits, Martin ^b   Berger, Walter ^a   Schmid, Katharina ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bronchial carcinoid; Epidermal growth factor receptor; Erlotinib; Everolimus; Large cell neuroendocrine lung carcinomas; Mammalian target of rapamycin; Synergism

Indexed keywords

CASPASE 3; CASPASE 7; CISPLATIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BRONCHUS CARCINOID; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PHASE; CHILD; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, BRONCHOGENIC; CARCINOMA, NEUROENDOCRINE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84870242259     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000337257     Document Type: Article

References (43)

1. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- To intermediate-Grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 2008; 26: 4311-4318.
2. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410.
3. Schmid K, Bago-Horvath Z, Berger W, Haitel A, Cejka D, Werzowa J, Filipits M, Herberger B, Hayden H, Sieghart W: Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 2010; 103: 622-628.
4. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H, Doppman J: Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991; 15: 529-553.
5. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN: Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22: 934-944. (Pubitemid 28364493)
6. Pardo OE, Arcaro A, Salerno G, Tetley TD, Valovka T, Gout I, Seckl MJ: Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene 2001; 20: 7658-7667. (Pubitemid 33111865)
7. Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G, Papotti M: Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 2010; 17: 977-987.
8. Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, degli Uberti EC: Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 2010; 17: 719-729.
9. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 2010; 17: 37-48.
10. Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I: Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new? World J Gastroenterol 2007; 13: 5877-5887. (Pubitemid 350148504)
11. Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D: Erlotinib in advanced non-small cell lung cancer: Efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010; 5: 1616-1622.
12. Rusch VW, Klimstra DS, Venkatraman ES: Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996; 62: 798-810. (Pubitemid 26301779)
13. Buck E, Eyzaguirre A, Brown E, Petti F, Mc-Cormack S, Haley JD, Iwata KK, Gibson NW, Griffin G: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5: 2676-2684. (Pubitemid 44848994)
14. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, Chen R, Clark DP, Forastiere A, Hidalgo M: Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007; 96: 952-959. (Pubitemid 46452288)
15. Skov BG, Krasnik M, Lantuejoul S, Skov T, Brambilla E: Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. J Thorac Oncol 2008; 3: 1410-1415.
16. Horvath Z, Murias M, Saiko P, Erker T, Handler N, Madlener S, Jaeger W, Grusch M, Fritzer-Szekeres M, Krupitza G, Szekeres T: Cytotoxic and biochemical effects of 3,3 -, 4,4 -, 5,5-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. Exp Hematol 2006; 34: 1377-1384. (Pubitemid 44374836)
17. Wesierska-Gadek J, Gueorguieva M, Wojciechowski J, Tudzarova-Trajkovska S: In vivo activated caspase-3 cleaves PARP-1 in rat liver after administration of the hepatocarcinogen N-nitrosomorpholine (NNM) generating the 85 kDa fragment. J Cell Biochem 2004; 93: 774-787. (Pubitemid 44264173)
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. (Pubitemid 38637993)
19. Herberger B, Berger W, Puhalla H, Schmid K, Novak S, Brandstetter A, Pirker C, Gruenberger T, Filipits M: Simultaneous blockade of the epidermal growth factor receptor/ mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol Cancer Ther 2009; 8: 1547-1556.
20. Chou TC, Talalay P: Quantitative analysis of dose-Effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
21. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005; 65: 9455-9462. (Pubitemid 41508014)
22. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME: Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 2006; 18: 355-360.
23. Welin S, Fjällskog ML, Saras J, Eriksson B, Janson ET: Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 2006; 84: 42-48. (Pubitemid 44973686)
24. Shi Y, Chen L, Li J, Lv YL, Sun Q, Wang LX, Jiao SC: Prognostic and predictive values of pERK1/2 and pAkt-1 expression in nonsmall cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol 2011; 32: 381-390.
25. Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, Breen TE, Yu M, Hanna NH: Gefitinib in patients with chemosensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial. Lung Cancer 2006; 52: 93-97. (Pubitemid 43340205)
26. Emery IF, Battelli C, Auclair PL, Carrier K, Hayes DM: Response to gefitinib and erlotinib in non-small cell lung cancer: A retrospective study. BMC Cancer 2009; 9: 333.
27. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G, SATURN investigators: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
28. Pelosi G, Scarpa A, Veronesi G, Spaggiari L, Del Curto B, Moore PS, Maisonneuve P, Sonzogni A, Masullo M, Viale G: A subset of high-Grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. Virchows Arch 2005; 447: 969-977. (Pubitemid 41719552)
29. Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, Smith WI Jr, Meltzer P, Wang Y, Giaccone G: Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci 2010; 107: 13040-13045.
30. Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM: Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer 2010; 17: 623-636.
31. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M, Grossman AB: Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-Endocrine tumour cell line. Neuroendocrinology 2008; 87: 168-181. (Pubitemid 351563811)
32. Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ: The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007; 85: 54-60. (Pubitemid 46550026)
33. Zitzmann K, Rüden J, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer CJ: Compensatory activation of Akt in response to mTOR and Raf inhibitors- A rationale for dual-Targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010; 295: 100-109.
34. Wiedenmann B, Pavel M, Kos-Kudla B: From targets to treatments: A review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology 2011; 94: 177-190.
35. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 2010; 28: 69-76.
36. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
37. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A: A Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010; 16: 5900-5907.
38. Birle DC, Hedley DW: Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol Cancer Ther 2006; 5: 2494-2502. (Pubitemid 44650913)
39. Papadimitrakopoulou V, Blumenschein GR, Leighl NB: A phase 1/2 study investigating the combination of RAD001 (everolimus) and erlotinib as 2nd and 3rd line therapy in patients with advanced non-small cell lung cancer previously treated with chemotherapy (C): Phase 1 results (abstract). J Clin Oncol 2008; 26(suppl):8051.
40. Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA: RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem 2010; 109: 320-328.
41. Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM: The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: Results of a pre-operative study. Breast Cancer Res Treat 2011; 128: 725-734.
42. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D: Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/ Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379-382.
43. Lin Y, Wang Z, Liu L, Chen L: Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-Tolerant human lung cancer cells. Lung Cancer 2011; 71: 291-297.